Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892852 | 0.88 | TLR7 (0.40) | TLR7TLR8 | |
| SCHEMBL2894947 | 0.83 | TLR7 (0.46) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL1951281 | 0.82 | GAA (0.47) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL1951282 | 0.82 | GAA (0.47) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL4165388 | 0.82 | CNR1 (0.43) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL4152852 | 0.81 | PDE4A (0.41) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL6414152 | 0.81 | SMN1; SMN2 (0.36) | TLR7 | |
| SCHEMBL5617629 | 0.80 | TLR7 (0.42) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL1960054 | 0.80 | TLR7 (0.42) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL5364616 | 0.80 | TLR7 (0.48) | TLR7CNR2LMNAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436178-B2 | Imidazoquinolines with immuno-modulating properties | ASTRAZENECA AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | IFNG, FCGRT, IFNAR1 | TLR7 267/4885TLR8 1392/4885PDE4A 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.